Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 15, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: May 11, 2006
- Previous Holding: 17,337,549 ADRs
- New Holding: 17,418,783 ADRs
- Average Price: $57.39
The increase resulted from a movement in the fund. Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the notification of the transaction.
Investor Verification Points
- Verify the impact of the fund movement on the total share count held by the GlaxoSmithKline US Retirement Savings Plan.
- Confirm the potential interest of Directors Dr. J P Garnier and Dr. T Yamada in the fund's holdings.
- Note that this filing does not contain operational or financial performance data for the period.